ECHS1 deficiency arises from loss-of-function variants in the gene encoding short-chain enoyl-CoA hydratase, a mitochondrial enzyme that sits at a critical juncture in the breakdown of valine, one of the three branched-chain amino acids. When the enzyme falters, reactive intermediates called methacrylyl-CoA and acryloyl-CoA accumulate and are captured by cysteine and cysteamine, forming the conjugates SCPC, SCEC, and DHMB that have been detected in patient samples. Clinicians have observed that higher levels of these metabolites correlate with earlier disease onset and more severe symptoms, which include developmental delay and regression, low muscle tone, dystonia, seizures, and often early death. Roughly half of patients also develop a secondary deficiency in the pyruvate dehydrogenase complex, the mitochondrial gatekeeper that converts pyruvate into acetyl-CoA to fuel the citric acid cycle, a failure hypothesized to result from toxic metabolite accumulation.

To test whether these valine-derived intermediates are genuinely harmful rather than merely correlated with disease, the researchers exposed mouse neuroblastoma cells, a neuronal model chosen for its relevance to the disorder’s neurological manifestations, to the three metabolites. The results were strikingly uneven. When cells received a pooled mixture of SCPC, SCEC, and DHMB at 5 millimolar each, viability dropped significantly, hinting at synergistic toxicity. Tested individually, SCPC emerged as the most potent offender: at 25 millimolar it slashed cell survival by roughly 75 percent, while SCEC showed no effect at the doses tested and DHMB produced only a modest 20 percent reduction at high concentrations.

Mitochondrial function told a similarly differentiated story. Using fluorescent probes to measure membrane potential and superoxide production, the team found that SCPC and DHMB each mildly increased membrane potential without boosting superoxide, whereas SCEC significantly elevated superoxide generation, a hallmark of respiratory chain stress. Seahorse extracellular flux assays, which track oxygen consumption in real time, confirmed that only SCPC impaired mitochondrial respiration, reducing basal, ATP-linked, and maximal respiration. SCEC and DHMB, by contrast, enhanced ATP production despite increasing proton leak, suggesting that each intermediate perturbs mitochondrial physiology through distinct mechanisms. The authors note an important caveat: the concentrations used in these experiments, 10 to 25 millimolar, exceed the levels reported in patient serum and urine, so the findings establish toxicity at high exposure rather than reproducing exact patient conditions.

Perhaps the most surprising result came when the researchers genetically deleted Echs1 in the same neuronal cells using CRISPR-Cas9. Contrary to expectations drawn from patient fibroblasts and non-neuronal models, the Echs1-deficient neuroblastoma cells did not show respiratory collapse. Although assembly of oxidative phosphorylation complexes II through IV was significantly impaired, the cells maintained basal respiration and actually increased ATP production, maximal respiration, spare respiratory capacity, and glycolytic activity. siRNA knockdown of Echs1 in wild-type cells reproduced this enhanced metabolic profile, confirming that the phenotype stemmed from Echs1 loss rather than an off-target effect of genome editing.

The explanation, the researchers discovered, lay in the cells’ developmental state. Echs1-deficient neuroblastoma cells displayed enlarged nuclei, longer neurite branches, and elevated expression of NeuN, a marker of mature neurons, all signs of premature neuronal differentiation. Because neuronal maturation involves extensive metabolic and mitochondrial remodeling, including increased mitophagy and altered glucose metabolism, this differentiation program may have masked the respiratory deficits seen in other cell types. Notably, when the team induced differentiation with retinoic acid, the OXPHOS assembly defects in Echs1-deficient cells worsened further rather than being explained away, indicating that the structural impairment is real but functionally compensated in this context. The authors speculate that loss of Echs1 may promote differentiation through epigenetic mechanisms, since reduced Echs1 has been shown to enhance histone lysine crotonylation, a chromatin modification that suppresses proliferation and drives differentiation in neural stem progenitor cells. Microcephaly reported in a subset of ECHS1 deficiency patients could reflect impaired neural progenitor proliferation through a similar route.

Extending the work into living animals, the team turned to a previously characterized compound heterozygous mouse model carrying a patient-associated F33S variant and a knockout allele. Under a standard diet, these mice accumulated SCPC in their blood but not SCEC, mirroring the preferential buildup of methacrylyl-CoA expected from lost enzyme activity. When the animals were fed chow supplemented with valine, SCPC levels roughly doubled, and the consequences were dramatic. In a pentylenetetrazol kindling protocol, in which mice receive repeated subconvulsant injections to provoke progressively severe seizures, ECHS1-deficient mice on the control diet developed seizures that killed half of them by the end of the regimen. Valine-supplemented mice began seizing after the very first injection and suffered 100 percent lethality by the ninth, while wild-type littermates on the same diet remained seizure free throughout.

Brain metabolism analysis, performed with microwave fixation to preserve the in vivo metabolic snapshot, revealed the mechanism in outline. Valine-supplemented ECHS1-deficient mice showed a two- to threefold increase in the alanine-to-lysine ratio and a smaller rise in the proline-to-lysine ratio, established biomarkers of pyruvate dehydrogenase complex dysfunction, along with an elevated NAD-to-NADH ratio indicating oxidative imbalance. Interestingly, these ratios were not elevated in ECHS1-deficient mice on the control diet despite their raised SCPC, suggesting that a threshold of metabolite accumulation must be crossed before measurable PDC impairment appears. Cellular energy charge, measured by ATP, ADP, and AMP levels, was preserved despite the redox shift, indicating that energy depletion was not the immediate driver of the worsened seizures.

The therapeutic test produced the study’s most cautionary finding. Starting at weaning, to model adolescent intervention, mice received a diet with 67 percent less valine, a reduction chosen to approximate the roughly 70 percent restriction that has shown benefit in some patients. The restricted diet did not lower SCPC levels in ECHS1-deficient mice and provided no protection against PTZ-induced seizures, which still killed half of the affected animals. Worse, SCEC, which had remained unremarkable under typical and excess valine intake, rose significantly under restriction. The authors propose that reduced valine availability may drive compensatory flux through alternative propionyl-CoA-producing pathways, including isoleucine, methionine, threonine, and odd-chain fatty acid catabolism, thereby increasing acryloyl-CoA and its cysteine conjugate. Valine restriction also induced oxidative imbalance and reduced energy charge in both genotypes, and it slowed weight gain in all mice, underscoring that substrate restriction carries global metabolic consequences independent of disease status.

Taken together, the study establishes SCPC as a plausible driver of mitochondrial dysfunction and disease severity in ECHS1 deficiency while revealing that the cellular response to Echs1 loss depends heavily on cell type and differentiation state. It also demonstrates that dietary valine modulation, at least when initiated in adolescence at a single restriction level, is a blunt instrument that reshapes metabolism in ways that may not help and may actively harm. The researchers emphasize that future work should employ titration-based dietary approaches, earlier intervention windows, and absolute quantification of valine intermediates to bridge the gap between mouse models and patient biochemistry. For a disorder with no established genotype-phenotype correlation and a clinical course that often ends early, the message is clear: effective therapy will likely require strategies that directly restore metabolic function rather than simply starving the pathway of its substrate.

Subject of Research: ECHS1 deficiency and valine metabolism toxicity

Article Title: Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency

Article References: Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency. (n.d.). https://doi.org/10.3389/fmolb.2026.1861051

Image Credits: AI Generated

DOI: 10.3389/fmolb.2026.1861051

Keywords: ECHS1 deficiency, valine metabolism, SCPC, mitochondrial dysfunction, pyruvate dehydrogenase complex, neurometabolic disease, seizures, dietary valine restriction, neuroblastoma cells, mouse model, metabolomics, rare disease